AnaptysBio (ANAB) News Today $23.39 -0.43 (-1.81%) Closing price 04:00 PM EasternExtended Trading$23.38 -0.01 (-0.04%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANAB Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Assenagon Asset Management S.A. Lowers Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)Assenagon Asset Management S.A. decreased its position in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 26.9% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 242,485 shares of the biotechnology company's stock after selling 89,273 shares during theJune 16 at 3:56 AM | marketbeat.comBank of America Corp DE Lowers Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB)Bank of America Corp DE cut its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 89.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 17,949 shares of the biotechnology company's stock after selJune 15 at 3:18 AM | marketbeat.comStocks With Rising Relative Price Strength: AnaptysBioJune 13, 2025 | msn.comStocks With Rising Relative Price Strength: AnaptysBioJune 13, 2025 | msn.comAnaptysBio: Rosnilimab's RA Data Sets The Stage For Blockbuster PotentialJune 10, 2025 | seekingalpha.comAnaptysBio, Inc. (NASDAQ:ANAB) Receives $42.38 Consensus Price Target from BrokeragesJune 8, 2025 | americanbankingnews.comStifel Nicolaus Remains a Buy on AnaptysBio (ANAB)June 7, 2025 | theglobeandmail.comAnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab AdvancementJune 6, 2025 | seekingalpha.comAnaptysBio (NASDAQ:ANAB) Trading Up 9.1% - What's Next?AnaptysBio (NASDAQ:ANAB) Stock Price Up 9.1% - Should You Buy?June 6, 2025 | marketbeat.comHC Wainwright & Co. Upgrades AnaptysBio (ANAB)June 5, 2025 | msn.comAnaptysBio (NASDAQ:ANAB) Stock Price Down 4.5% - Should You Sell?AnaptysBio (NASDAQ:ANAB) Shares Down 4.5% - Should You Sell?June 5, 2025 | marketbeat.comAnaptys gains after updated data from mid-stage trial for arthritis therapyJune 5, 2025 | msn.comAnaptysBio, Inc. (NASDAQ:ANAB) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) have earned an average rating of "Moderate Buy" from the ten ratings firms that are covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation, six have given a buy recommendation and onJune 5, 2025 | marketbeat.comJ&J sends AnaptysBio lower with mid-stage trial data for anti-inflammatory agentJune 4, 2025 | msn.comAnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning PointJune 4, 2025 | benzinga.comAnaptysBio (NASDAQ:ANAB) Shares Gap Up - Here's WhyAnaptysBio (NASDAQ:ANAB) Shares Gap Up - Here's What HappenedJune 4, 2025 | marketbeat.comAnaptysBio’s Rosnilimab Shows ‘Best-in-Disease’ Profile in Phase 2b RA TrialJune 4, 2025 | insidermonkey.comAnaptysBio (NASDAQ:ANAB) Upgraded to Buy at HC WainwrightHC Wainwright upgraded shares of AnaptysBio from a "neutral" rating to a "buy" rating and set a $38.00 target price for the company in a research note on Wednesday.June 4, 2025 | marketbeat.comAnaptysBio Rise 6% After Results From Rheumatoid Arthritis Treatment RosnilimabJune 3, 2025 | marketwatch.comStocks Generating Improved Relative Strength: AnaptysBioJune 3, 2025 | msn.comAnaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RAJune 3, 2025 | globenewswire.comMillennium Management LLC Sells 185,049 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)Millennium Management LLC decreased its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 55.8% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 146,517 shares of the biotechnology company's stock after selling 185,049 sJune 3, 2025 | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Shares Purchased by Squarepoint Ops LLCSquarepoint Ops LLC increased its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 81.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 80,870 shares of the biotechnology company's stock aftJune 1, 2025 | marketbeat.comBeyond The Numbers: 5 Analysts Discuss AnaptysBio StockMay 30, 2025 | benzinga.comAnaptysBio (NASDAQ:ANAB) Shares Up 6.6% - Here's WhyAnaptysBio (NASDAQ:ANAB) Shares Up 6.6% - Here's What HappenedMay 30, 2025 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Earns "Outperform" Rating from WedbushWedbush reissued an "outperform" rating and set a $40.00 price target on shares of AnaptysBio in a research note on Thursday.May 30, 2025 | marketbeat.comVoloridge Investment Management LLC Trims Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB)Voloridge Investment Management LLC lowered its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 49.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 87,513 shares of the biotechnology company's stock after selling 85,708 shares duringMay 30, 2025 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Shares Gap Up After Analyst UpgradeAnaptysBio (NASDAQ:ANAB) Shares Gap Up on Analyst UpgradeMay 29, 2025 | marketbeat.comAnaptysBio to Host Investor Call for Phase 2b RENOIR Trial Data on Rosnilimab for Rheumatoid ArthritisMay 29, 2025 | nasdaq.comGuggenheim Boosts AnaptysBio (NASDAQ:ANAB) Price Target to $90.00Guggenheim increased their price objective on AnaptysBio from $54.00 to $90.00 and gave the company a "buy" rating in a research report on Wednesday.May 29, 2025 | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Shares Purchased by Two Sigma Investments LPTwo Sigma Investments LP increased its stake in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 66.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 352,034 shares of the biotechnology company's stock after acquiring an additioMay 29, 2025 | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Position Lessened by BNP Paribas Financial MarketsBNP Paribas Financial Markets trimmed its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 65.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,126 shares of the bMay 29, 2025 | marketbeat.comAnaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025May 27, 2025 | globenewswire.comTwo Sigma Advisers LP Boosts Position in AnaptysBio, Inc. (NASDAQ:ANAB)Two Sigma Advisers LP raised its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 58.1% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 293,300 shares of the biotechnology company's stock after purchasing an additional 107,800 shares duringMay 27, 2025 | marketbeat.comWoodline Partners LP Buys 25,094 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)Woodline Partners LP grew its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 5.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 485,073 shares of the biotechnology company's stock after purchasingMay 26, 2025 | marketbeat.comNorthern Trust Corp Boosts Position in AnaptysBio, Inc. (NASDAQ:ANAB)Northern Trust Corp grew its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 10.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 219,986 shares of the biotechnology company's stock after buying an additional 20,073 shares durMay 26, 2025 | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Shares Bought by Rafferty Asset Management LLCRafferty Asset Management LLC lifted its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 83.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 70,883 shares of the biotechnologMay 24, 2025 | marketbeat.comFrazier Life Sciences Management L.P. Reduces Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)Frazier Life Sciences Management L.P. reduced its holdings in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 28.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,573,719 shares of the biotechnology company's stock aftMay 23, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Sells 27,030 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)D. E. Shaw & Co. Inc. lessened its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 12.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 197,107 shares of the biotechnology company's stock after selliMay 22, 2025 | marketbeat.comSoleus Capital Management L.P. Invests $5.48 Million in AnaptysBio, Inc. (NASDAQ:ANAB)Soleus Capital Management L.P. purchased a new stake in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 414,000 shares of the biotechnology company's stock, valued at approximately $5,481,000. Soleus Capital MMay 21, 2025 | marketbeat.comGraham Capital Management L.P. Purchases Shares of 18,954 AnaptysBio, Inc. (NASDAQ:ANAB)Graham Capital Management L.P. purchased a new stake in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund purchased 18,954 shares of the biotechnology company's stock, valued at approximately $251,000. Graham Capital MMay 21, 2025 | marketbeat.comSanofi Purchases New Stake in AnaptysBio, Inc. (NASDAQ:ANAB)Sanofi purchased a new stake in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 821,917 shares of the biotechnology company's stock, valued at approximately $10,May 19, 2025 | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Shares Acquired by Jacobs Levy Equity Management Inc.Jacobs Levy Equity Management Inc. raised its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 85.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 85,381 shares of the biotechnology company's stock after buyiMay 19, 2025 | marketbeat.comDimensional Fund Advisors LP Decreases Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB)Dimensional Fund Advisors LP lessened its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 67.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 31,608 shares of the biotechnology company's stock after selling 64,364 shares during the pMay 19, 2025 | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Shares Bought by Ensign Peak Advisors IncEnsign Peak Advisors Inc grew its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 184.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 215,454 shares of the biotechnology company's stock after purchasing an additional 1May 18, 2025 | marketbeat.comGranahan Investment Management LLC Invests $1.40 Million in AnaptysBio, Inc. (NASDAQ:ANAB)Granahan Investment Management LLC acquired a new stake in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 106,079 shares of the biotechnology company's stock, valued at approximately $1,404,000.May 13, 2025 | marketbeat.comAnaptysBio, Inc. (ANAB): Among the Unstoppable Growth Stocks to Invest in NowMay 12, 2025 | msn.comWells Fargo & Company MN Trims Stake in AnaptysBio, Inc. (NASDAQ:ANAB)Wells Fargo & Company MN lessened its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 59.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,120 shares of the biotechnolMay 12, 2025 | marketbeat.comBridgefront Capital LLC Makes New $252,000 Investment in AnaptysBio, Inc. (NASDAQ:ANAB)Bridgefront Capital LLC acquired a new position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 19,011 shares of the biotechnology company's stockMay 11, 2025 | marketbeat.comQ2 Earnings Forecast for AnaptysBio Issued By HC WainwrightAnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Investment analysts at HC Wainwright lowered their Q2 2025 earnings per share estimates for shares of AnaptysBio in a research report issued on Tuesday, May 6th. HC Wainwright analyst E. Bodnar now expects that the biotechnology company will earn ($1May 10, 2025 | marketbeat.com Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Email Address ANAB Media Mentions By Week ANAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANAB News Sentiment▼1.310.56▲Average Medical News Sentiment ANAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANAB Articles This Week▼45▲ANAB Articles Average Week Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ascentage Pharma Group International News Today ImmunityBio News Today MoonLake Immunotherapeutics News Today Organon & Co. News Today Immunovant News Today Mirum Pharmaceuticals News Today Xenon Pharmaceuticals News Today Amneal Pharmaceuticals News Today Apellis Pharmaceuticals News Today NewAmsterdam Pharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ANAB) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersThis is not your typical AI storyThe market’s biggest AI winners? You’ve never heard of them. Everyone’s obsessed with AI stocks like Nvidia...Market Traders Daily | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWill I be blacklisted?The President’s tour of the Middle East… the deal for Ukraine’s mineral rights… Elon’s strange time in Washing...Porter & Company | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | SponsoredElon’s End Game Is Going Live -- And It Could Make You a FortuneThe media and the so-called experts have laughed at Elon Musk his entire career. CBS called PayPal “one of ...The Oxford Club | SponsoredSorry about the swear wordWhat a huge few months for Bitcoin. First, Bitcoin hit $100,000… Then, Donald Trump pledged to create an...Manward Press | SponsoredGold Just Jumped Again. Here’s How to Get PaidGold prices just spiked again. As I write this, gold is trading near $3,400 an ounce. But here's the thi...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ANAB Stock Free ANAB Stock Alerts